Coagulation

JCAD, a junctional protein, independently predicts major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients with residual lipid and inflammatory risks, suggesting a key role in coagulation and fibrinolysis and a promising target to mitigate high residual ischemic risk.